Day 2 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter:
“Day 2 of GU24 ASCO Highlights
1. UNITE: EV after chemo/Avelumab
2. MSI-H in urothelial cancer
3. AMBASSADOR: Pembro in adj locally advanced UC
1. UNITE: EV + Pembro now SoC in 1L. But good portion of patients currently on Chemo —> Avelumab. Role of EV after Chemo/Avelumab (retrospective data):
– ORR: 54% and mOS of 13.3mos
– Some great toxicity management pearls for EV by Parminder Singh.
2. MSI High in urothelial cancer:
– Approximately 2% of patients (low number and agreed, we need better markers in UC). BUT, response rates to IO are great (is dual checkpoint the way to go? We just saw data from CM8HW from GI24)
– Also, MSI via IHC is readily checked in the community for other tumor types.
3. AMBASSADOR: Adjuvant Pembro in muscle invasive locally advanced urothelial cancer (pT-any/N+, pT2/3, pT4)
– Improved DFS (benefit seen with CPS ≥ 10 or negative PDL1). 29mos vs 14mos (HR: 0.69)
– OS not met at this interim analysis (HR: 0.98).”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023